CD19 and precursor B-cell acute lymphoblastic leukemia: However, when B2m-knockout BCR-ABL1+ B-ALL mice were treated, the combination of imatinib and CD19@NP/17-DMAG only slightly extended survival by 4 days over the vehicle control and by 2 days over imatinib plus 17-DMAG (Figure 6P).